| P2093 | author name string | Wen Chen | |
| | Zhihui Xie | |
| | Hua Xie | |
| | Yuanyuan Xiao | |
| | Guoyou Qin | |
| | Naiqing Zhao | |
| | Zhenyi Shao | |
| P2860 | cites work | Understanding the Warburg effect: the metabolic requirements of cell proliferation | Q24604760 |
| | Cancer statistics, 2010 | Q27860525 |
| | Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression | Q28272474 |
| | Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. | Q33897308 |
| | Clinicopathological significance and prognostic value of lactate dehydrogenase A expression in gastric cancer patients | Q35114759 |
| | Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients | Q35835193 |
| | Modelling prognostic factors in advanced pancreatic cancer | Q36882688 |
| | Hypoxia and hypoxia-inducible factors: master regulators of metastasis | Q37801762 |
| | Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia | Q39068039 |
| | Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. | Q39448204 |
| | N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation | Q39468979 |
| | Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer | Q43060720 |
| | High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents | Q43061476 |
| | Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells | Q43537462 |
| | Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis | Q43954468 |
| | Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. | Q50950502 |
| | Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas | Q66921417 |
| | Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung | Q70082611 |
| | Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer | Q72893971 |
| | Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma | Q80040456 |
| | Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy | Q85782703 |
| | Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy | Q85893467 |
| | High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma | Q86509280 |
| | Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy | Q87475904 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | e6399 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Varying postresection lactate dehydrogenase with overall survival of early stage pancreatic cancer patients: A retrospective study | |
| P478 | volume | 96 | |